Section Contents Menu

This is an archived document. It is no longer current information and has been superseded. The current document can be found online.

Updated: April 21, 2006Original Publication date: April 10, 2006

Dear Healthcare Practitioner:

This is to provide updated information on the recent increase in reports of a rare but serious fungal infection of the eye in soft contact lens wearers in the U.S. The infection, a fungal keratitis caused by the Fusarium fungus, may cause vision loss requiring corneal transplants.

New Information

On April 13, 2006, Bausch and Lomb announced that it is withdrawing all ReNu with MoistureLoc products and is recommending that consumers stop using ReNu with MoistureLoc immediately.

Both the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) continue to investigate reports of fungal keratitis in an effort to determine all contributing factors and/or products that place contact lens wearers at increased risk for Fusarium keratitis.

This Notification will continue to be updated as more information becomes available.

Updated Recommendations

For healthcare providers:

Advise patients to stop using Bausch and Lomb ReNu with MoistureLoc products immediately, discard all remaining MoistureLoc solution and use an alternative cleaning/disinfecting product.

If a patient presents with a microbial keratitis, consider that a fungal infection may be involved.

Prior to initiating immediate treatment, an eye care professional should obtain a specimen for laboratory analysis.

Stop using Bausch and Lomb ReNu with MoistureLoc products and discard all remaining MoistureLoc solution including partially used or unopened bottles.

Consult your eye care professional concerning use of an appropriate alternative cleaning/disinfecting product.

Consider performing a “rub and rinse” lens cleaning method, rather than a no rub method, regardless of which cleaning/disinfecting solution used, in order to minimize the number of germs and reduce the chances of infection.

Continue to Follow proper lens care practices:

Wash hands with soap and water, and dry (lint-free method) before handling lenses.

Wear and replace lenses according to the schedule prescribed by the doctor.

Follow the specific lens cleaning and storage guidelines from the doctor and the solution manufacturer.

In an MMWR Dispatch dated April 10, 2006, CDC stated that it received reports of 109 cases of suspected fungal keratitis in 17 different states. Although the majority of case patients have yet to be interviewed, complete data are available for 30 of them. Twenty-eight of the 30 wore soft contact lenses. Preliminary information obtained by CDC from patient interviews indicates that 26 of these patients remembered which products they used, and that all 26 reported using a Bausch & Lomb ReNu brand contact lens solution in the month prior to the onset of infection. Patients reported using a variety of different ReNu types from multiple different product lots. Five of the patients reported using other solutions in addition to the ReNu product. Nine of the patients reported wearing lenses overnight, a known risk factor for microbial keratitis. Eight required corneal transplantation. Strain typing of the organism is ongoing. This document can be found at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm55d410a1.htm.

CDC and FDA are investigating these case reports. Also, investigations by CDC, state and local health departments, FDA, and manufacturers of contact lens solutions are underway to define specific behaviors or products that place contact lens wearers at increased risk for Fusarium keratitis.

Clusters of Fusarium keratitis were reported among contact lens users in Asia beginning in February 2006. At that time, Bausch & Lomb voluntarily suspended sales of its ReNu multipurpose solutions in Singapore and Hong Kong, pending their investigations, after multiple reports of Fusarium keratitis among contact lens users there.

Background on Microbial Keratitis

Microbial keratitis is a severe infection of the cornea. Risk factors for infection include trauma (generally with plant material), chronic ocular surface diseases, immunodeficiency, and rarely, contact lens use. There are an estimated 30 million soft contact lens users in the United States. The annual incidence of microbial keratitis is estimated to be 4-21 per 10,000 soft contact lens users, depending on overnight lens use. Fungal keratitis is a condition more prevalent in warm climates. In the southernmost United States, fungal keratitis comprises up to 35% of microbial keratitis cases compared with 1% in New York. The proportion of fungal keratitis due to Fusarium spp. also varies by region, from 25-62%.

Reporting Adverse Events

FDA and CDC are very interested in gathering information related to fungal keratitis in contact lens users. We encourage you to report these infections to FDA. FDA will be sharing reported information with CDC. You can report directly to MedWatch, the FDA’s voluntary reporting program. You may submit reports to MedWatch by phone at 1-800-FDA-1088; by FAX at 1-800-FDA-0178; by mail to MedWatch, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857-9787; or online.

Please include the following information (if available) on the MedWatch reporting form:

Contact lens solutions trade names and lot numbers.

Contact lens type, trade name and mode of wear (extended or daily wear).

Special patient characteristics, including whether the patient was immunocompromised (e.g., used topical or systemic corticosteroids or had diabetes), or had any ocular trauma, surgery, or chronic eye problem.

Topical ocular medications used to treat the patient (including trade names and lot number if available).

Getting More Information

Additional information regarding the withdrawal of ReNu with MoistureLoc can be obtained from Bausch and Lomb by calling 1-888-666-2258.

If you have questions about this Notification, please contact FDA's Division of of Small Manufacturers, International and Consumer Assistance (DSMICA) by e-mail at dsmica@fda.hhs.gov or by phone at 1-800-638-2041 or 301-796-7100

CDRH Preliminary Public Health Notifications are intended to quickly share device-related safety information with healthcare providers when the available information and our understanding of an issue are still evolving. We will revise them as new information merits and so encourage you to check this site for updates.